MarketCap
Facebook
X
Telegram
Abeona Therapeutics ROCE Ratio | ABEO
Annual ROCE Ratio Abeona Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -47.08 | -69.53 | -93.19 | -90.22 | -142.68 | -44.4 | -41.74 | -37.76 | -16.08 | -23.24 | -23.6 | -22.88 | 45.57 | 88.1 | 93.71 | 141.4 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 141.4 | -142.68 | -17.73 |
Quarterly ROCE Ratio Abeona Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.65 | -46.14 | -48.08 | -58.56 | -64.56 | -68.08 | -72.56 | -71.09 | -79.15 | -83.78 | -92.46 | -95.91 | -92.71 | -113.58 | -121.72 | -158.72 | -209.89 | -185.44 | -168.82 | -120.12 | -59.28 | -48.39 | -42.79 | -63.11 | -58.74 | -67.97 | -76.04 | -54.37 | -57.17 | -54.03 | -43.92 | -37.05 | -30.41 | -24.91 | -26.24 | -25.27 | -25.89 | -27.82 | -28.95 | -32.45 | -34.73 | -34.05 | -29.29 | -37.32 | -42.51 | -29.07 | -9.69 | 7.17 | 15.36 | 38.57 | 67.88 | 62.35 | 79.04 | 81.31 | 58.07 | 56.82 | 52.04 | 54.52 | 70.87 | 75.98 | 14.81 | 28.86 | 12.21 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 81.31 | -209.89 | -36.84 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Praxis Precision Medicines
PRAX
|
-37.15 | $ 337.69 | 1.42 % | $ 7.6 B |  USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
-152.35 | $ 3.78 | 0.53 % | $ 291 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-54.09 | $ 1.31 | -5.07 % | $ 138 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
-35.66 | $ 6.62 | -3.36 % | $ 1.24 B | USA |
 |
PolyPid Ltd.
PYPD
|
-226.3 | $ 6.3 | 0.96 % | $ 103 M |  Israel |
 |
Outlook Therapeutics
OTLK
|
208.35 | $ 0.46 | -0.84 % | $ 16 M | USA |
 |
uniQure N.V.
QURE
|
-24.32 | $ 22.7 | -0.39 % | $ 1.31 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
-46.89 | $ 16.13 | -1.71 % | $ 1.59 B | USA |
 |
Rafael Holdings
RFL
|
-50.31 | $ 1.11 | 2.45 % | $ 57 M | USA |
 |
REGENXBIO
RGNX
|
-48.13 | $ 7.66 | -5.08 % | $ 395 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
30.28 | $ 43.83 | 4.22 % | $ 788 M | USA |
 |
SELLAS Life Sciences Group
SLS
|
-39.9 | $ 8.38 | -2.39 % | $ 914 M | USA |
 |
Celsion Corporation
CLSN
|
-207.46 | - | -6.63 % | $ 13.9 M | USA |
 |
Tenax Therapeutics
TENX
|
-58.09 | $ 1.69 | -5.34 % | $ 66.3 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
4.3 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
3539.01 | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
24.32 | - | - | $ 867 M |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-41.41 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-1.18 | - | - | $ 4.9 B |  Britain |
 |
Rezolute
RZLT
|
-81.8 | $ 4.01 | 3.83 % | $ 417 M | USA |
 |
Midatech Pharma plc
MTP
|
-71.74 | - | -18.52 % | $ 27.3 M | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
-401.27 | $ 0.61 | -8.44 % | $ 65.1 M | Britain |
 |
MorphoSys AG
MOR
|
-14.33 | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
-149.7 | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
766.36 | - | -1.58 % | $ 28.1 M |  China |
 |
Celyad Oncology SA
CYAD
|
-439.8 | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
-27.82 | $ 1.62 | -3.57 % | $ 89.7 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-45.4 | - | - | $ 3.37 B | China |
 |
Shattuck Labs
STTK
|
-61.34 | $ 4.86 | -2.71 % | $ 338 M | USA |
|
Silence Therapeutics plc
SLN
|
-65.22 | $ 19.78 | 0.15 % | $ 2.8 B | Britain |
 |
Stoke Therapeutics
STOK
|
-5.71 | $ 27.16 | -1.98 % | $ 1.61 B | USA |
 |
Sutro Biopharma
STRO
|
119.57 | $ 10.08 | -5.0 % | $ 85.7 M | USA |
 |
Soligenix
SNGX
|
-213.96 | $ 0.32 | -6.35 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
7.9 | $ 42.54 | -1.0 % | $ 48.7 B | Israel |
 |
China SXT Pharmaceuticals
SXTC
|
-23.43 | $ 2.99 | -3.55 % | $ 2.03 M | China |
 |
Spruce Biosciences
SPRB
|
-85.04 | $ 46.36 | -6.04 % | $ 35.5 M | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
2.92 | $ 20.9 | -0.9 % | $ 33 B |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
-5.59 | $ 28.77 | 4.15 % | $ 1.62 B | USA |
 |
Galapagos NV
GLPG
|
9.07 | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
-53.02 | $ 4.92 | -2.57 % | $ 1.09 B | USA |
 |
Teligent, Inc.
TLGT
|
69.22 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-40.79 | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
13.56 | $ 64.27 | 1.4 % | $ 9.28 B | USA |
 |
Aphria Inc.
APHA
|
-2.49 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-14.58 | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
-44.26 | - | -6.00 % | $ 238 M | USA |
 |
Trevi Therapeutics
TRVI
|
-26.85 | $ 14.92 | -2.55 % | $ 2.01 B | USA |